LIVIVO - Search results -

Search results

Result 1 - 10 of total 34

Search options

Article ; Online: Sphingosine kinase 1 as an anticancer therapeutic target.

Gao, Ying / Gao, Fei / Chen, Kan / Tian, Mei-li / Zhao, Dong-li

2015 Volume 9, Page(s) 3239–3245

Abstract: ... sphingosine kinase 1 (SK1) levels is predictive of a poor prognosis, and SK1 overexpression may confer ... resistance to chemotherapeutics. The SK/sphingosine-1-phosphate (S1P)/sphingosine-1-phosphate receptor (S1PR ... may be an effective anticancer therapeutic strategy, particularly in the context of overcoming ...

Abstract	The development of chemotherapeutic resistance is a major challenge in oncology. Elevated sphingosine kinase 1 (SK1) levels is predictive of a poor prognosis, and SK1 overexpression may confer resistance to chemotherapeutics. The SK/sphingosine-1-phosphate (S1P)/sphingosine-1-phosphate receptor (S1PR) signaling pathway has been implicated in the progression of various cancers and in chemotherapeutic drug resistance. Therefore, SK1 may represent an important target for cancer therapy. Targeting the SK/S1P/S1PR signaling pathway may be an effective anticancer therapeutic strategy, particularly in the context of overcoming drug resistance. This review summarizes our current understanding of the role of SK/S1P/S1PR signaling in cancer and development of SK1 inhibitors.
MeSH term(s)	Animals ; Antineoplastic Agents/therapeutic use ; Apoptosis/drug effects ; Drug Resistance, Neoplasm ; Enzyme Inhibitors/therapeutic use ; Humans ; Lysophospholipids/metabolism ; Molecular Targeted Therapy ; Neoplasm Metastasis ; Neoplasms/drug therapy ; Neoplasms/enzymology ; Neoplasms/pathology ; Phosphotransferases (Alcohol Group Acceptor)/antagonists & inhibitors ; Phosphotransferases (Alcohol Group Acceptor)/metabolism ; Receptors, Lysosphingolipid/metabolism ; Signal Transduction/drug effects ; Sphingosine/analogs & derivatives ; Sphingosine/metabolism
Chemical Substances	Antineoplastic Agents ; Enzyme Inhibitors ; Lysophospholipids ; Receptors, Lysosphingolipid ; sphingosine 1-phosphate (26993-30-6) ; Phosphotransferases (Alcohol Group Acceptor) (EC 2.7.1.-) ; sphingosine kinase (EC 2.7.1.-) ; Sphingosine (NGZ37HRE42)
Language	English
Publishing date	2015
Publishing country	New Zealand
Document type	Journal Article ; Research Support, Non-U.S. Gov't ; Review
ZDB-ID	2451346-5
ISSN	1177-8881 ; 1177-8881
ISSN (online)	1177-8881
ISSN	1177-8881
DOI	10.2147/DDDT.S83288
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Full text

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- Full text online
- Order with fees

Article ; Online: Sphingosine kinase 1 as an anticancer therapeutic target

Gao Y / Gao F / Chen K / Tian ML / Zhao DL

Drug Design, Development and Therapy, Vol 2015, Iss default, Pp 3239-

2015 Volume 3245

Abstract: ... The development of chemotherapeutic resistance is a major challenge in oncology. Elevated sphingosine kinase 1 ... and development of SK1 inhibitors. Keywords: sphingosine kinase 1, S1P, S1PR, inhibitors, cancer ... to chemotherapeutics. The SK/sphingosine-1-phosphate (S1P)/sphingosine-1-phosphate receptor (S1PR) signaling pathway ...

Abstract	Ying Gao,1,* Fei Gao,2,* Kan Chen,3,* Mei-li Tian,1 Dong-li Zhao1 1Department of Radiotherapy Oncology, First Affiliated Hospital of Xi’an Jiaotong University, 2Department of Neurology, First Affiliated Hospital of Xi’an Medical University, Xi’an, 3School of Life Sciences, Zhejiang Sci-Tech University, Hangzhou, People’s Republic of China *These authors contributed equally to this work Abstract: The development of chemotherapeutic resistance is a major challenge in oncology. Elevated sphingosine kinase 1 (SK1) levels is predictive of a poor prognosis, and SK1 overexpression may confer resistance to chemotherapeutics. The SK/sphingosine-1-phosphate (S1P)/sphingosine-1-phosphate receptor (S1PR) signaling pathway has been implicated in the progression of various cancers and in chemotherapeutic drug resistance. Therefore, SK1 may represent an important target for cancer therapy. Targeting the SK/S1P/S1PR signaling pathway may be an effective anticancer therapeutic strategy, particularly in the context of overcoming drug resistance. This review summarizes our current understanding of the role of SK/S1P/S1PR signaling in cancer and development of SK1 inhibitors. Keywords: sphingosine kinase 1, S1P, S1PR, inhibitors, cancer, therapy
Keywords	Medicine ; R ; Medicine (General) ; R5-920 ; Therapeutics. Pharmacology ; RM1-950
Language	English
Publishing date	2015-06-01T00:00:00Z
Publisher	Dove Medical Press
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Investigation of sphingosine kinase 1 inhibitory potential of cinchonine and colcemid targeting anticancer therapy.

Roy, Sonam / Khan, Shama / Jairajpuri, Deeba Shamim / Hussain, Afzal / Alajmi, Mohamed F / Islam, Asimul / Luqman, Suaib / Parvez, Suhel / Hassan, Md Imtaiyaz

Journal of biomolecular structure & dynamics

2021 Volume 40, Issue 14, Page(s) 6350–6362

Abstract: Sphingosine kinase 1 (SphK1) and sphingosine-1-phosphate (S1P) signaling regulates numerous ... for the development of anticancer therapy. New drug molecules targeting the S1P signaling are required owing ... in breast, lung, colon, and hepatocellular carcinomas. SphK1 is considered an attractive drug target ...

Abstract	Sphingosine kinase 1 (SphK1) and sphingosine-1-phosphate (S1P) signaling regulates numerous diseases such as cancer, diabetes, and inflammation-related ailments, rheumatoid arthritis, atherosclerosis, and multiple sclerosis. The importance of SphK1 in chemo-resistance has been extensively explored in breast, lung, colon, and hepatocellular carcinomas. SphK1 is considered an attractive drug target for the development of anticancer therapy. New drug molecules targeting the S1P signaling are required owing to its pleiotropic nature and association with multiple downstream targets. Here, we have investigated the binding affinity and SphK1 inhibitory potential of cinchonine and colcemid using a combined molecular docking and simulation studies followed by experimental analysis. These compounds bind to SphK1 with a significantly high affinity and subsequently inhibit kinase activity (IC
MeSH term(s)	Cinchona Alkaloids ; Demecolcine ; Molecular Docking Simulation ; Phosphotransferases (Alcohol Group Acceptor)/chemistry
Chemical Substances	Cinchona Alkaloids ; Phosphotransferases (Alcohol Group Acceptor) (EC 2.7.1.-) ; sphingosine kinase (EC 2.7.1.-) ; cinchonine (V43X79NZCD) ; Demecolcine (Z01IVE25KI)
Language	English
Publishing date	2021-02-10
Publishing country	England
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	49157-3
ISSN	1538-0254 ; 0739-1102
ISSN (online)	1538-0254
ISSN	0739-1102
DOI	10.1080/07391102.2021.1882341
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2093: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: The sphingosine kinase-1/sphingosine-1-phosphate axis in cancer: Potential target for anticancer therapy.

Zheng, Xiangjin / Li, Wan / Ren, Liwen / Liu, Jinyi / Pang, Xiaocong / Chen, Xiuping / Kang, De / Wang, Jinhua / Du, Guanhua

Pharmacology & therapeutics

2018 Volume 195, Page(s) 85–99

Abstract: ... for growth and development of cells. Sphingosine kinase (SPHK) is an important regulator for keeping this balance ... cells and tumor angiogenesis. There are two isoenzymes of sphingosine kinase, SPHK1 and SPHK2. SPHK1 is ... Sphingolipid metabolites, such as ceramide, sphingosine and sphingosine-1-phosphate (S1P), play ...

Abstract	Sphingolipid metabolites, such as ceramide, sphingosine and sphingosine-1-phosphate (S1P), play many important roles in cellular activities. Ceramide and sphingosine inhibit cell proliferation and induce cell apoptosis while S1P has the opposite effect. Maintaining a metabolic balance of sphingolipids is essential for growth and development of cells. Sphingosine kinase (SPHK) is an important regulator for keeping this balance. It controls the level of S1P and plays important roles in proliferation, migration, and invasion of cancer cells and tumor angiogenesis. There are two isoenzymes of sphingosine kinase, SPHK1 and SPHK2. SPHK1 is ubiquitously expressed in most cancers where it promotes survival and proliferation, while SPHK2 is restricted to only certain tissues and its functions are not well characterized. SPHK1 is currently considered as a novel target for the treatment of cancers. Targeting SPHK1 would provide new strategies for cancer treatment and improve the prognosis of cancer patients. Here we review and summarize the current research findings on the SPHK1-S1P axis in cancer from many aspects including structure, expression, regulation, mechanism, and potential inhibitors.
MeSH term(s)	Animals ; Drug Resistance, Neoplasm ; Humans ; Lysophospholipids/metabolism ; Neoplasms/drug therapy ; Neoplasms/metabolism ; Phosphotransferases (Alcohol Group Acceptor)/chemistry ; Phosphotransferases (Alcohol Group Acceptor)/metabolism ; Sphingosine/analogs & derivatives ; Sphingosine/metabolism
Chemical Substances	Lysophospholipids ; sphingosine 1-phosphate (26993-30-6) ; Phosphotransferases (Alcohol Group Acceptor) (EC 2.7.1.-) ; sphingosine kinase (EC 2.7.1.-) ; Sphingosine (NGZ37HRE42)
Language	English
Publishing date	2018-10-19
Publishing country	England
Document type	Journal Article ; Research Support, Non-U.S. Gov't ; Review
ZDB-ID	194735-7
ISSN	1879-016X ; 0163-7258
ISSN (online)	1879-016X
ISSN	0163-7258
DOI	10.1016/j.pharmthera.2018.10.011
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1183: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article: Molecular docking analysis of sphingosine kinase 1 inhibitors for cancer management.

Barnawi, Jameel

Bioinformation

2023 Volume 19, Issue 5, Page(s) 571–576

Abstract: Sphingosine kinase 1 (SK1) catalyses the conversion of sphingosine to the signalling mediator ... target for anticancer therapy. In this study, a virtual screening approach was used to screen a total ... sphingosine 1-phosphate. This is essential for cell survival and proliferation. SK1 is frequently ...

Abstract	Sphingosine kinase 1 (SK1) catalyses the conversion of sphingosine to the signalling mediator sphingosine 1-phosphate. This is essential for cell survival and proliferation. SK1 is frequently overexpressed in various cancer types, promoting tumor progression. SK1 has been well documented as a promising target for anticancer therapy. In this study, a virtual screening approach was used to screen a total of 1068 natural compounds, with the aim of identifying potential inhibitors of SK1. The top hit compounds, namely CNP0296172, CNP0368143, CNP0380570, and CNP0290815, were selected based on their strong binding affinity and specificity towards the SK1 binding pocket. Notably, these selected hit compounds exhibited a higher affinity towards the SK1 binding pocket when compared to the positive control compound (PF-543). Furthermore, these compounds were found to meet the necessary drug like criteria, thus rendering them suitable candidates for further experimental validation as potential anticancer agents.
Language	English
Publishing date	2023-05-31
Publishing country	Singapore
Document type	Journal Article
ZDB-ID	2203786-X
ISSN	0973-2063
ISSN	0973-2063
DOI	10.6026/97320630019571
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Evaluation of binding and inhibition mechanism of dietary phytochemicals with sphingosine kinase 1: Towards targeted anticancer therapy.

Gupta, Preeti / Mohammad, Taj / Dahiya, Rashmi / Roy, Sonam / Noman, Omar Mohammed Ali / Alajmi, Mohamed F / Hussain, Afzal / Hassan, Md Imtaiyaz

Scientific reports

2019 Volume 9, Issue 1, Page(s) 18727

Abstract: Sphingosine kinase 1 (SphK1) has recently gained attention as a potential drug target ...

Abstract	Sphingosine kinase 1 (SphK1) has recently gained attention as a potential drug target for its association with cancer and other inflammatory diseases. Here, we have investigated the binding affinity of dietary phytochemicals viz., ursolic acid, capsaicin, DL-α tocopherol acetate, quercetin, vanillin, citral, limonin and simvastatin with the SphK1. Docking studies revealed that all these compounds bind to the SphK1 with varying affinities. Fluorescence binding and isothermal titration calorimetric measurements suggested that quercetin and capsaicin bind to SphK1 with an excellent affinity, and significantly inhibits its activity with an admirable IC
MeSH term(s)	Humans ; Lysophospholipids/metabolism ; Molecular Dynamics Simulation ; Neoplasms ; Phosphotransferases (Alcohol Group Acceptor)/metabolism ; Phosphotransferases (Alcohol Group Acceptor)/physiology ; Phytochemicals/metabolism ; Phytochemicals/therapeutic use ; Protein Binding/physiology ; Quercetin/pharmacology ; Sphingosine/metabolism
Chemical Substances	Lysophospholipids ; Phytochemicals ; Quercetin (9IKM0I5T1E) ; Phosphotransferases (Alcohol Group Acceptor) (EC 2.7.1.-) ; sphingosine kinase (EC 2.7.1.-) ; Sphingosine (NGZ37HRE42)
Language	English
Publishing date	2019-12-10
Publishing country	England
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2615211-3
ISSN	2045-2322 ; 2045-2322
ISSN (online)	2045-2322
ISSN	2045-2322
DOI	10.1038/s41598-019-55199-3
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Evaluation of ellagic acid as an inhibitor of sphingosine kinase 1: A targeted approach towards anticancer therapy.

Gupta, Preeti / Mohammad, Taj / Khan, Parvez / Alajmi, Mohamed F / Hussain, Afzal / Rehman, Md Tabish / Hassan, Md Imtaiyaz

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

2019 Volume 118, Page(s) 109245

Abstract: Sphingosine kinase 1 (SphK1) is one of the central enzymes of sphingolipid metabolism whose high ... an appreciable binding affinity. Kinase inhibition assay revealed an excellent inhibitory action of EA ...

Abstract	Sphingosine kinase 1 (SphK1) is one of the central enzymes of sphingolipid metabolism whose high expression level is presumed to be correlated with cancer and other inflammatory diseases. Using a virtual screening approach and in vitro studies, we have identified the ellagic acid (EA), a dietary polyphenol, as a potent inhibitor of SphK1. Molecular docking study has suggested a strong binding affinity of EA to the SphK1. Fluorescence binding and isothermal titration calorimetry (ITC) measurements has also indicated an appreciable binding affinity. Kinase inhibition assay revealed an excellent inhibitory action of EA towards SphK1 (IC
MeSH term(s)	A549 Cells ; Antineoplastic Agents/pharmacology ; Cell Death/drug effects ; Cell Proliferation/drug effects ; Ellagic Acid/chemistry ; Ellagic Acid/pharmacology ; HEK293 Cells ; Humans ; Molecular Docking Simulation ; Molecular Targeted Therapy ; Phosphotransferases (Alcohol Group Acceptor)/antagonists & inhibitors ; Phosphotransferases (Alcohol Group Acceptor)/chemistry ; Phosphotransferases (Alcohol Group Acceptor)/metabolism ; Principal Component Analysis ; Protein Kinase Inhibitors/pharmacology ; Protein Structure, Secondary ; Recombinant Proteins/isolation & purification ; Spectrometry, Fluorescence ; Thermodynamics
Chemical Substances	Antineoplastic Agents ; Protein Kinase Inhibitors ; Recombinant Proteins ; Ellagic Acid (19YRN3ZS9P) ; Phosphotransferases (Alcohol Group Acceptor) (EC 2.7.1.-) ; sphingosine kinase (EC 2.7.1.-)
Language	English
Publishing date	2019-07-25
Publishing country	France
Document type	Journal Article
ZDB-ID	392415-4
ISSN	1950-6007 ; 0753-3322 ; 0300-0893
ISSN (online)	1950-6007
ISSN	0753-3322 ; 0300-0893
DOI	10.1016/j.biopha.2019.109245
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Ud II Zs.198: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Discovering Gummadiol and Isoarboreol as potential inhibitors of sphingosine kinase 1: virtual screening and MD simulation studies.

Elasbali, Abdelbaset Mohamed / Al-Soud, Waleed Abu / Alhassan, Hassan H / Mousa Elayyan, Afnan Elayyan / Kamal, Mehnaz / Alanazi, Hamad / Alharbi, Bandar / Alharethi, Salem Hussain / Mohamed, Bashir M

Journal of biomolecular structure & dynamics

2023 Volume 41, Issue 22, Page(s) 12789–12797

Abstract: Sphingosine kinase 1 (SphK1) dysfunction is well-known to be linked to various severe diseases ... of cancer and its progression, it is considered a notable drug target for anticancer therapy. Small molecule ... of phytochemicals in anticancer therapeutics and presented Gummadiol and Isoarboreol as promising inhibitors ...

Abstract	Sphingosine kinase 1 (SphK1) dysfunction is well-known to be linked to various severe diseases, including breast, lung, prostate, and hematological cancers. Due to its crucial function in the onset of cancer and its progression, it is considered a notable drug target for anticancer therapy. Small molecule inhibitors with high specificity and efficacy towards SphK1 are needed for their therapeutic use. In order to find possible SphK1 inhibitors, we conducted a stepwise structure-based virtual screening of plant-based molecules available from the IMPPAT library. A multi-step virtual screening, including physicochemical and ADMET evaluation, PAINS, molecular docking, PASS analysis followed by molecular dynamics (MD) simulation and principal component analysis, identifies two compounds, Gummadiol and Isoarboreol, against SphK1. All-atom MD simulations were performed for 100 ns which examined the structural changes and stability of the docked complexes in the aqueous environment. The time evolution data of structural deviations and compactness, PCA and free energy landscapes suggested that the binding of Gummadiol and Isoarboreol with SphK1 is considerably stable throughout the trajectory. The study highlighted the use of phytochemicals in anticancer therapeutics and presented Gummadiol and Isoarboreol as promising inhibitors of SphK1.Communicated by Ramaswamy H. Sarma.
MeSH term(s)	Humans ; Molecular Dynamics Simulation ; Molecular Docking Simulation ; Phosphotransferases (Alcohol Group Acceptor)/chemistry ; Phosphotransferases (Alcohol Group Acceptor)/metabolism ; Neoplasms
Chemical Substances	sphingosine kinase (EC 2.7.1.-) ; Phosphotransferases (Alcohol Group Acceptor) (EC 2.7.1.-)
Language	English
Publishing date	2023-01-16
Publishing country	England
Document type	Journal Article
ZDB-ID	49157-3
ISSN	1538-0254 ; 0739-1102
ISSN (online)	1538-0254
ISSN	0739-1102
DOI	10.1080/07391102.2023.2167864
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2093: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Phase I study of opaganib, an oral sphingosine kinase 2-specific inhibitor, in relapsed and/or refractory multiple myeloma.

Kang, Yubin / Sundaramoorthy, Pasupathi / Gasparetto, Cristina / Feinberg, Daniel / Fan, Shengjun / Long, Gwynn / Sellars, Emily / Garrett, Anderson / Tuchman, Sascha A / Reeves, Brandi N / Li, Zhiguo / Liu, Bei / Ogretmen, Besim / Maines, Lynn / Ben-Yair, Vered Katz / Smith, Charles / Plasse, Terry

Annals of hematology

2022 Volume 102, Issue 2, Page(s) 369–383

Abstract: ... therapeutic drugs that do not share similar mechanisms of action with currently available agents. Sphingosine kinase ... 2 (SK2) is an innovative molecular target for anticancer therapy. We previously reported ... stable disease for 3 months. SK2 is an innovative molecular target for antimyeloma therapy. The first ...

Abstract	Multiple myeloma (MM) remains an incurable disease and there is an unmet medical need for novel therapeutic drugs that do not share similar mechanisms of action with currently available agents. Sphingosine kinase 2 (SK2) is an innovative molecular target for anticancer therapy. We previously reported that treatment with SK2 inhibitor opaganib inhibited myeloma tumor growth in vitro and in vivo in a mouse xenograft model. In the current study, we performed a phase I study of opaganib in patients with relapsed/refractory multiple myeloma (RRMM). Thirteen patients with RRMM previously treated with immunomodulatory agents and proteasome inhibitors were enrolled and treated with single-agent opaganib at three oral dosing regimens (250 mg BID, 500 mg BID, or 750 mg BID, 28 days as a cycle). Safety and maximal tolerated dose (MTD) were determined. Pharmacokinetics, pharmacodynamics, and correlative studies were also performed. Opaganib was well tolerated up to a dose of 750 mg BID. The most common possibly related adverse event (AE) was decreased neutrophil counts. There were no serious AEs considered to be related to opaganib. MTD was determined as at least 750 mg BID. On an intent-to-treat basis, one patient (7.7%) in the 500 mg BID dose cohort showed a very good partial response, and one other patient (7.7%) achieved stable disease for 3 months. SK2 is an innovative molecular target for antimyeloma therapy. The first-in-class SK2 inhibitor opaganib is generally safe for administration to RRMM patients, and has potential therapeutic activity in these patients. Clinicaltrials.gov: NCT02757326.
MeSH term(s)	Humans ; Animals ; Mice ; Multiple Myeloma/drug therapy ; Multiple Myeloma/pathology ; Phosphotransferases (Alcohol Group Acceptor)/therapeutic use ; Proteasome Inhibitors/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Dexamethasone
Chemical Substances	sphingosine kinase (EC 2.7.1.-) ; Phosphotransferases (Alcohol Group Acceptor) (EC 2.7.1.-) ; Proteasome Inhibitors ; Dexamethasone (7S5I7G3JQL)
Language	English
Publishing date	2022-12-03
Publishing country	Germany
Document type	Clinical Trial, Phase I ; Journal Article
ZDB-ID	1064950-5
ISSN	1432-0584 ; 0939-5555 ; 0945-8077
ISSN (online)	1432-0584
ISSN	0939-5555 ; 0945-8077
DOI	10.1007/s00277-022-05056-7
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Uh III Zs.181: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: A chemical screen for modulators of mRNA translation identifies a distinct mechanism of toxicity for sphingosine kinase inhibitors.

Corman, Alba / Kanellis, Dimitris C / Michalska, Patrycja / Häggblad, Maria / Lafarga, Vanesa / Bartek, Jiri / Carreras-Puigvert, Jordi / Fernandez-Capetillo, Oscar

PLoS biology

2021 Volume 19, Issue 5, Page(s) e3001263

Abstract: ... signaling pathway were the most represented class. In addition, we identified that inhibitors of sphingosine kinases ... regulators, and consistent with current knowledge, inhibitors of the mechanistic target of rapamycin (mTOR ... of SPHK inhibitors being developed as anticancer agents are independent of SPHKs. ...

Abstract	We here conducted an image-based chemical screen to evaluate how medically approved drugs, as well as drugs that are currently under development, influence overall translation levels. None of the compounds up-regulated translation, which could be due to the screen being performed in cancer cells grown in full media where translation is already present at very high levels. Regarding translation down-regulators, and consistent with current knowledge, inhibitors of the mechanistic target of rapamycin (mTOR) signaling pathway were the most represented class. In addition, we identified that inhibitors of sphingosine kinases (SPHKs) also reduce mRNA translation levels independently of mTOR. Mechanistically, this is explained by an effect of the compounds on the membranes of the endoplasmic reticulum (ER), which activates the integrated stress response (ISR) and contributes to the toxicity of SPHK inhibitors. Surprisingly, the toxicity and activation of the ISR triggered by 2 independent SPHK inhibitors, SKI-II and ABC294640, the latter in clinical trials, are also observed in cells lacking SPHK1 and SPHK2. In summary, our study provides a useful resource on the effects of medically used drugs on translation, identified compounds capable of reducing translation independently of mTOR and has revealed that the cytotoxic properties of SPHK inhibitors being developed as anticancer agents are independent of SPHKs.
MeSH term(s)	Animals ; Cell Line ; Drug Design ; Enzyme Inhibitors/pharmacology ; High-Throughput Screening Assays/methods ; Humans ; Image Processing, Computer-Assisted/methods ; Lysophospholipids/metabolism ; Mass Spectrometry/methods ; Molecular Structure ; Phosphotransferases (Alcohol Group Acceptor)/antagonists & inhibitors ; Phosphotransferases (Alcohol Group Acceptor)/metabolism ; Protein Biosynthesis/drug effects ; Protein Biosynthesis/physiology ; RNA, Messenger/genetics ; RNA, Messenger/metabolism ; Signal Transduction/drug effects ; Small Molecule Libraries ; Sphingosine/metabolism
Chemical Substances	Enzyme Inhibitors ; Lysophospholipids ; RNA, Messenger ; Small Molecule Libraries ; Phosphotransferases (Alcohol Group Acceptor) (EC 2.7.1.-) ; sphingosine kinase (EC 2.7.1.-) ; Sphingosine (NGZ37HRE42)
Language	English
Publishing date	2021-05-25
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2126776-5
ISSN	1545-7885 ; 1544-9173
ISSN (online)	1545-7885
ISSN	1544-9173
DOI	10.1371/journal.pbio.3001263
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6193: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

Full text online

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito